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2572 | Anal. Methods, 2013, 5, 2572–Rapid determination of indapamide in human urine
using novel low-density solvent based ultrasound
assisted emulsiﬁcation microextraction coupled with
high performance liquid chromatography-variable
wavelength detection
Abilasha Ramkumar,a Vinoth Kumar Ponnusamya and Jen-Fon Jen*ab
Indapamide belongs to the class of thiazide-type diuretic drugs and is widely used in the treatment of
hypertension and nephrolithiasis. In this work, a simple, rapid and eﬃcient low density solvent (LDS)
based ultrasound assisted emulsiﬁcation microextraction (USAEME) method combined with high
performance liquid chromatography-variable wavelength detection (HPLC-VWD) was investigated for
the determination of a popular drug of abuse, indapamide, in human urine samples. The target
compound was extracted from acidiﬁed sample solution with a few microliter amount of LDS by a
USAEME method. The inﬂuence of several important experimental variables such as selection of the
extraction solvent and its volume, ultrasonication time, pH and ionic strength were thoroughly
examined and optimized. Under optimal conditions, the calibration was linear in concentration range
from 1–100 ng mL1 with a correlation coeﬃcient of 0.9977 for the target analyte. The limit of
detection based on signal to noise ratio of 3 was 0.3 ng mL1 and the relative standard deviations
varied from 1.2–6.6%. The proposed method provides a rapid, sensitive, low cost, easy to handle, and
convenient procedure to determine indapamide in human urine samples.1 Introduction
3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-
yl)benzamide (indapamide) is a diuretic and antihypertensive
drug and some of its pharmacodynamic activity is related to a
thiazide-type eﬀect.1 Clinical uses of indapamide include the
treatment of nephrogenic diabetes insipidus, hypertension,
hypercalciuria, glaucoma, and edema, among other diseases.2,3
Indapamide (a popular drug of abuse) is also misused by
athletes in sports for several reasons including the reduction of
body weight, to reduce urinary concentration of other pro-
hibited substances in order to avoid a positive doping test and
to overcome uid retention caused by the use of anabolic
steroids.4,5 Indapamide belongs to the group of diuretics that
are banned substances in sports since 1986.6 Moreover, to date
the pharmacokinetic proles of indapamide pills compared
with conventional tablets in vivo is unknown. The analytical
determination of indapamide is desirable7 taking into account
that its overdose might lead to severe hyponatraemia, with
symptoms varying from nausea to seizures and coma andHsing University, Taichung 402, Taiwan.
6-4-22862547; Tel: +886-4-22853148
hnology, Asia University, Wufeng District,
2577hypokalemia,8,9 which could lead to fatal arrhythmia.10 In 2007, a
case report linking indapamide and hyperparathyroidism was
published.11 According to literature evidence, indapamide deter-
mination has been accomplished in various biological uids like
urine,12,13 serum14 and plasma.15,16 Therefore, a simple, rapid and
eﬃcient analysis method is needed for the determination of
indapamide in urine sample so as to evaluate the pharmacoki-
netic parameters and also to monitor its drug abuse in sports.
Most sample preparation techniques available for the
extraction of indapamide in various biological matrices include
liquid–liquid extraction (LLE) and solid phase extraction
(SPE).17–19 However, the disadvantage of these methods is that
they are either involved in several extraction steps or yield poor
separation from the biological sample's endogenous interfer-
ences, low extraction recovery and the need for a large amount
of internal standard.17,18 Ideally, sample-preparation techniques
should be fast, inexpensive and compatible with a range of
analytical instruments, so the current trend is towards
decreasing the quantities of organic solvents, simplication
and miniaturization of the sample-preparation steps.20 To fulll
this purpose, liquid-phase microextraction (LPME) techniques
like single drop microextraction (SDME), hollow-ber LPME
and dispersive liquid–liquid microextraction (DLLME) were
developed.21–25More recently, a novel microextraction technique
developed by Garcia-Jares et al., named ultrasound-assistedThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlineemulsication microextraction (USAEME) was developed,26
based on the emulsication of few microliters of water-immis-
cible extraction solvent in the aqueous sample solution by
ultrasound radiation. The usage of ultrasound energy leads to
enlargement of the contact surface between two immiscible
liquids due to reduction of droplet size of the extractant phase,
thereby facilitating mass-transfer of the analyte between the two
phases. However, the main disadvantage of USAEME is that the
extraction solvent must have a higher density than water in
order to be sedimented by centrifugation, typically chlorinated
solvents such as chlorobenzene were used, which is potentially
toxic to human health and the environment. Recently, low
density organic solvents were applied to substitute chloro-
solvents in USAEME due to toxicity consideration.27,28
Hence, the goal of the present work was to investigate and
develop a rapid and eﬃcient low density solvent (LDS) based
USAEME method coupled with high performance liquid chro-
matography-variable wavelength detection (HPLC-VWD) for the
analysis of indapamide in human urine samples. It is to be
noted that this is the rst report of the determination of inda-
pamide in human urine using LDS-USAEME, thus paving way as
a good alternative for routine analysis of indapamide in human
urine samples with advantages of simplicity, reliability, cost
eﬀectiveness and minimized matrix interferences. The eﬀect of
various experimental conditions on the extraction of indapa-
mide are investigated and discussed in detail. The optimized
procedure was successfully applied to the determination of the
target analyte in human urine samples.2 Experimental
2.1 Reagents and solutions
All chemicals used in this work were of ACS reagent grade.
Indapamide (99.9%) was purchased from Fluka Chimika
(Buchs, Switzerland). 1-Dodecanol (density, 0.83 g mL1) and 1-
undecanol (density, 0.82 g mL1), were purchased from Merck
Chemicals (Darmstadt, Germany). HPLC-grade acetonitrile
(ACN), hydrochloric acid (HCl), sodium chloride (NaCl) and
sodium hydroxide (NaOH) were purchased from Merck (Darm-
stadt, Germany). Ultrapure water for all aqueous solutions was
produced in the laboratory using Barnstead Nanopure water
system (Barnstead, New York, USA). Stock solutions (1 mg L1 of
the analyte) were prepared by dissolving the analyte in meth-
anol and stored in brown glass bottles with polymer-lined caps
and kept at 2 C. Working standard solutions were obtained
daily by diluting the stock solutions.
Urine samples used for evaluation of themethodwere collected
in glass bottles from two healthy volunteers. Obtained urine
samples were diluted with ultrapure water (1 : 1) and was adjusted
to pH 3 by adding 1 M HCl and ltered through 0.45 mm cellulose
acetatemembrane lters and stored at20 C prior to being used.2.2 Instrumentation
The liquid chromatography equipment included an Agilent
1100 Series equipped HPLC system with manual injection and
variable wavelength detector (VWD). A personal computerThis journal is ª The Royal Society of Chemistry 2013equipped with Agilent ChemStation program was used for data
acquisition and processing. Extraction solvent collection and
injections were carried out using a 50 mL HPLC microsyringe
(SGE, Ringwood, Australia). Separation of the target analyte was
accomplished using a Macherey-Nagel Nucleodur C18 HTec
(5 mm, 250 mm  4.6 mm ID) column (Du¨ren, Germany). The
mobile phase was phosphate buﬀer (adjusted to pH 3 with
o-phosphoric acid) and acetonitrile (40 : 60, v/v) at a ow rate of
1 mL min1. Detection was set at 240 nm.29 Under these chro-
matographic conditions, the target analyte could be baseline
separated.2.3 LDS-USAEME procedure
10 mL of spiked sample solution was placed in a 15 mL screw-
cap glass test tube with conical bottom. 40 mL of 1-undecanol (as
extraction solvent) was rapidly injected into the sample solution
by a 0.5 mL syringe (SGE, Ringwood, Australia). The resulting
mixture was subsequently immersed into an ultrasonic bath
(model D80, Delta, Taiwan) for 2 min at 25 C at ultrasound
frequency and power of 43 KHz (80 W) for extraction. During
this step, a turbid cloudy solution was formed in the test tube
and analyte in the urine sample was extracted into the ne
droplets of 1-undecanol because of the increased contact area
between the extraction solvent and urine. Then the formed
emulsion was centrifuged for 3 min at 4500 rpm during which
the dispersed ne particles of the extraction solvent collected at
the top of the conical test tube. The collected extraction solvent
was measured using a 50 mL HPLC microsyringe (SGE, Ring-
wood, Australia), from which 10 mL was diluted with mobile
phase (1 : 1) and injected into the HPLC-VWD for analysis.3 Results and discussion
3.1 Selection of extraction solvent
The choice of an appropriate organic extraction solvent is of
high importance in the USAEME process. The prime require-
ments for the extraction solvent include low toxicity, immisci-
bility in aqueous samples, low density, high extraction
capability for indapamide and good chromatographic behavior.
Based on the aforementioned conditions, four organic solvents
including 1-octanol, 1-decane, 1-undecanol and 1-dodecanol
were investigated in the current research. Fig. 1 demonstrates
the peak areas obtained by using these extractants for the
extraction of 100 ng mL1 of the indapamide in 10 mL sample
solution under USAEME conditions. Results revealed that
1-undecanol has the highest extraction eﬃciency for the target
analyte compared to other extractants. Therefore, 1-undecanol
was chosen for subsequent experiments.3.2 Eﬀect of extraction solvent volume
In order to investigate the eﬀect of volume of 1-undecanol on
extraction eﬃciency, diﬀerent volumes of 1-undecanol from 30
to 70 mL were investigated. By increasing the 1-undecanol
volume in the range of 30–70 mL at 10 mL intervals, the extrac-
tion eﬃciency gradually increased from 30 to 40 mL. Fig. 2
depicts the change trend of peak area versus 1-undecanolAnal. Methods, 2013, 5, 2572–2577 | 2573
Fig. 1 Eﬀect of extraction solvent on the extraction eﬃciency. Sample: 10 mL of
sample solution (100 ng mL1 of indapamide) at pH 3. Volume of extraction
solvent: 40 mL, extraction time: 2min, centrifugation time: 3min at 4500 rpm, n¼ 3.
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View Article Onlinevolume. It was clear that 1-undecanol showed poor extraction
eﬃciency at low volume (30 mL). When 1-undecanol volume was
increased to 40 mL, higher peak response was achieved because
concentration of the analyte (indapamide) in the extraction
solvent attained the maximum extraction eﬃciency under the
proposed extraction procedure. Any further increase in
1-undecanol volume resulted in decreased extraction eﬃciency
due to the dilution of the analyte in a higher volume of
1-undecanol.30 Therefore, 40 mL 1-undecanol was selected as an
optimal extraction solvent volume in subsequent extractions.
3.3 Eﬀect of ultrasonication time
Ultrasonication time is one of the main factors in USAEME
because ultrasonication decreases the droplet size andFig. 2 Eﬀect of volume of extraction solvent on extraction eﬃciency Extraction
solvent: 1-undecanol, sample and extraction conditions: as in Fig. 1 except volume
of extraction solvent.
2574 | Anal. Methods, 2013, 5, 2572–2577disperses the organic extraction solvent uniformly within the
aqueous solution, resulting in large contact surface area
between the organic extraction solvent and the aqueous sample,
thereby resulting in very rapid transport of analyte from the
aqueous phase to the organic phase. As is evident from Fig. 3,
extraction eﬃciency increased until 2 min of ultrasonication,
which was suﬃcient for obtaining maximum extraction eﬃ-
ciency and with further increase in ultrasonication time, the
extraction eﬃciency remained almost constant probably
because of attainment of equilibrium due to the complete
dispersal of the extraction solvent.31 Hence short ultra-
sonication time of 2 min was selected for further studies.
3.4 Eﬀect of pH
In general, sample pH determines the existant state of analytes,
thereby aﬀecting extraction eﬃciency. Since analytes in neutral
forms are much easier to extract than those in ionic forms,
partition coeﬃcient and extraction ability of the system are
enhanced. Experimental results showed that the extraction
eﬃciency of indapamide remains unchanged from pH 2–7 and
any further increase in pH resulted in a decrease in extraction
eﬃciency. The reason can be attributed to the fact that under
alkaline pH conditions, the ionized form of the indapamide
might be formed, resulting in increased aqueous solubility,
thereby decreasing extraction eﬃciency.32 Therefore pH 3 was
used for further experiments for the better extraction with good
precision for the acidied urine sample.
3.5 Eﬀect of ionic strength
Generally, the addition of salt decreases the solubility of ana-
lytes in aqueous sample and enhances their distribution in
organic phase. However, it can be seen from Fig. 4 that addition
of NaCl resulted in a gradual decrease in extraction eﬃciency.
The probable reason for the decrease in extraction eﬃciency
could be because of decreased solubility of extraction solvent inFig. 3 Eﬀect of extraction (ultrasonication) time on extraction eﬃciency sample
and extraction conditions as in Fig. 2 except extraction time.
This journal is ª The Royal Society of Chemistry 2013
Fig. 4 Eﬀect of salt concentration on extraction eﬃciency sample and extraction
conditions as in Fig. 3.
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View Article Onlineaqueous sample solution in the presence of salt.33 On the basis
of the above observations; no salt was added for further
extractions.Fig. 5 Chromatogram of indapamide in (a) blank (non-spiked) urine sample and (b)
analyte.
This journal is ª The Royal Society of Chemistry 20133.6 Evaluation of quantitative aspects and its application
Analytical characteristics of the proposed method such as linear
range, correlation coeﬃcient, limits of detection and precision
were investigated under the optimal experimental conditions.
Precision, expressed as relative standard deviation (RSD), was
evaluated in terms of repeatability by performing three replicate
extractions of spiked urine (100 ng mL1) and it ranged from
1.2–6.6%. For spiked urine standards, indapamide exhibited
good linearity in the range of 1–100 ng mL1 with a correlation
coeﬃcient (R2) value of 0.9977. Limit of detection (LOD) was
calculated as the analyte concentration equal to 3 times the
standard deviation of the blank signal divided by the slope of
the calibration curve and it was found to be 0.3 ng mL1 and
limit of quantication (LOQ) was calculated as the analyte
concentration equal to 10 times the standard deviation of the
blank signal divided by the slope of the calibration curve and it
was found to be 1.1 ng mL1.
Validation of the proposed method was examined by spiking
three analyte free urine samples with concentrations of 50, 25
and 10 ng mL1 collected from three healthy adults (aged 24–30
years) and subjecting the sample to LDS-USAEME followed by
HPLC-VWD analysis. Prior to LDS-USAEME, the urine samplesspiked urine sample, by the present method. Spiked sample: 50 ng mL1 of target
Anal. Methods, 2013, 5, 2572–2577 | 2575
Table 1 Analytical results of indapamide in urine samples by the proposed method
Urine sample
Spiked concentration
(ng mL1)
Concentration found
in real sample (ng mL1)
Relative recovery
(%)
RSD (%,
n ¼ 3)
Volunteer I 50 NDa 109.6 2.6
Volunteer II ND 107.5 5.8
Volunteer I 25 ND 80 1.8
Volunteer II ND 110.7 6.7
Volunteer I 10 ND 119 5.0
Volunteer II ND 114 2.1
a Not detectable.
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View Article Onlinewere adjusted to the required pH and ltered through 0.45 mm
cellulose acetate membrane lters and stored at 20 C till
analysis time. Obtained urine samples were run to determine
the absence of the target drug. Experimental results exhibited
that no indapamide was detected in the urine samples (Fig. 5a).
As can be seen in Fig. 5b, a typical chromatogram of the spiked
(50 ngmL1) urine sample obtained by the LDS-USAEME-HPLC-
VWDmethod does not have any interferences from endogenous
matrix components, thereby revealing good sensitivity and good
cleanup of the developed method. When the sample was spiked
with 50, 25 and 10 ng mL1 of indapamide and extracted (Table
1), relative recoveries obtained ranged from 80–119% with RSDs
ranging from 1.8–6.7%, thereby proving that this LDS-USAEME-
HPLC-VWD is a rapid, accurate and sensitive method for the
analysis of indapamide in human urine.
3.7 Matrix eﬀect
Matrix eﬀect could change the instrumental response of the
analyte when a component of urine co-elutes with the analyte of
interest and causes suppression or enhancement in extraction
eﬃciency relative to the analyte eluting in the absence of the
matrix component, thereby resulting in erroneous results. In
this work, the matrix eﬀect was investigated by analyzing urine
samples covering a wide range of creatinine contents (1–50 mg
L1). Experimental results showed that excellent recoveries
ranging from 94.6–101.7% were obtained for creatinine
concentrations ranging from 1–50 mg L1, proving that creati-
nine adjusted urine did not have any considerable inuence on
extraction eﬃciency. Another way to reduce the impact ofTable 2 Comparison of the proposed method with other methods
Method LOQ (ng mL1)
Extraction sol
volume (mL)
SPE-HPLC-UV 10 0.3
LLE-HPLC-AMPa 1 8
SPE-HPLC-AMP 1 2
LLE-UPLCb-UV 1 5
LLE-HPLC-ESIc-MS 0.75 5
LLE-HPLC–UV 5 4
USAEME-HPLC-VWD 1.1 0.04
a AMP – Amperometric detection. b UPLC – Ultra-performance liquid ch
d Total extraction time refers to the overall time taken for the extraction
wherever applicable.
2576 | Anal. Methods, 2013, 5, 2572–2577matrix eﬀects is by the dilution of urine samples. In order to
check the eﬀect of urine dilution on extraction eﬃciency/
recovery, the samples were subjected to diﬀerent degrees (1, 5,
10 and 20) of dilution and it can be seen from experimental
results that good enrichment factors were obtained that
remained almost constant at diﬀerent dilutions of the urine
sample, thus proving the absence of any matrix interferences
using 1-undecanol as the extraction solvent for LDS-USAEME-
HPLC-VWD of indapamide. As a result of the above studies, it
can be concluded that matrix inuences did not aﬀect our
proposed method under optimal conditions.
3.8 Comparison of the present technique with other
reported methods
Table 2 compares the gures of merit of the proposed method
with other reported methods for the extraction of indapamide
from various samples of interest. It can be clearly seen from the
table that the volume of extraction solvent used in the proposed
method is highly minimal when compared to other reported
methods, and the limits of quantication (LOQs) are compa-
rable. These merits emphasize the fact that the proposed
method is highly cost eﬀective, environment friendly and rapid.
4 Conclusion
In the present study, LDS-USAEME combined with HPLC-VWD
has been successfully applied for the extraction and determina-
tion of indapamide in human urine samples. On comparison
with other conventional sample preparation methods such asvent
Total extraction timed (min) Reference
5 19
45 12
2 12
5.5 34
15 14
12 29
5 Present method
romatography. c ESI-MS – Electrospray ionization-mass spectrometry.
procedure, including ultrasonication, centrifugation and vortex mixing,
This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineLLE and SPE, the proposed method oﬀers advantages such as
simplicity, minimum matrix eﬀects, lower consumption of
organic solvent, ease of operation and relatively short analysis
time. Moreover, the use of less toxic low density extraction
solvent facilitated the easy retrieval of the extraction solvent
microdrops, thereby making the sample preparation procedure
simple and environment friendly. Moreover, the linear concen-
tration range of the proposed method covers the common drug
abuse cutoﬀ concentrations in both the initial screening test and
the conrmatory test. Experimental results indicate that the
present method can be used as a method of choice for the simple
and eﬃcient extraction of indapamide in human urine samples.Acknowledgements
The authors thank the National Science Council of Taiwan
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